Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+37.27%
|
-
|
|
Feb 19
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+28.04%
|
-
|
|
Feb 19
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
616
+4.23%
|
-
|
|
Feb 19
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,220
+3.62%
|
-
|
|
Feb 19
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,320
+26.59%
|
-
|
|
Dec 15
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
32,535
-91.08%
|
$422,955
$13.56 P/Share
|
|
Dec 13
2023
|
James L Tyree |
SELL
Open market or private sale
|
Direct |
9,000
-47.27%
|
$117,000
$13.32 P/Share
|
|
Dec 13
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
9,000
-0.96%
|
$117,000
$13.58 P/Share
|
|
Dec 07
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
36,800
-53.08%
|
$404,800
$11.85 P/Share
|
|
Nov 21
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
18,665
-21.21%
|
$186,650
$10.26 P/Share
|
|
Nov 20
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
14,594
-14.23%
|
$160,534
$11.26 P/Share
|
|
Nov 17
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
3,541
-3.34%
|
$46,033
$13.04 P/Share
|
|
Oct 25
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
5,704
-0.41%
|
$108,376
$19.4 P/Share
|
|
Oct 24
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
5,200
-4.67%
|
$98,800
$19.11 P/Share
|
|
Oct 24
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Oct 23
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
49,987
-3.5%
|
$949,753
$19.97 P/Share
|
|
Oct 16
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
3,333
-0.35%
|
$66,660
$20.9 P/Share
|
|
Oct 10
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
5,200
-2.34%
|
$114,400
$22.43 P/Share
|
|
Oct 10
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Oct 05
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
14,251
-0.49%
|
$356,275
$25.18 P/Share
|
|
Oct 03
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
75,690
-4.99%
|
$1,892,250
$25.49 P/Share
|
|
Sep 28
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
2,289
-0.15%
|
$54,936
$24.12 P/Share
|
|
Sep 27
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
11,257
-0.74%
|
$270,168
$24.47 P/Share
|
|
Sep 26
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
29,805
-0.64%
|
$685,515
$23.67 P/Share
|
|
Sep 26
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
5,200
-1.58%
|
$119,600
$23.5 P/Share
|
|
Sep 26
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Sep 25
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,458
-0.2%
|
$323,908
$26.25 P/Share
|
|
Sep 22
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
9,042
-0.29%
|
$244,134
$27.32 P/Share
|
|
Sep 21
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
7,549
-0.24%
|
$211,372
$28.36 P/Share
|
|
Sep 20
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
6,000
-5.35%
|
$162,000
$27.96 P/Share
|
|
Sep 20
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+5.08%
|
$36,000
$6.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-94.59%
|
$300,000
$30.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+48.61%
|
$60,000
$6.0 P/Share
|
|
Sep 19
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Direct |
32,167
-87.18%
|
$836,342
$26.68 P/Share
|
|
Sep 18
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
30,292
-57.23%
|
$696,716
$23.69 P/Share
|
|
Sep 18
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
3,334
-0.7%
|
$80,016
$24.99 P/Share
|
|
Sep 15
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
3,333
-0.35%
|
$73,326
$22.03 P/Share
|
|
Sep 15
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
10,400
-4.57%
|
$218,400
$21.93 P/Share
|
|
Sep 15
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
10,400
+8.19%
|
$62,400
$6.0 P/Share
|
|
Sep 14
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
25,276
-23.52%
|
$556,072
$22.04 P/Share
|
|
Sep 13
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
29,800
-21.92%
|
$625,800
$21.14 P/Share
|
|
Sep 13
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
19,032
-12.47%
|
$399,672
$21.79 P/Share
|
|
Sep 13
2023
|
John W Smither |
SELL
Open market or private sale
|
Direct |
900
-11.51%
|
$18,000
$20.78 P/Share
|
|
Sep 12
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,265
-10.63%
|
$445,830
$22.13 P/Share
|
|
Sep 11
2023
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
6,920
+46.95%
|
-
|
|
Sep 11
2023
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+0.71%
|
-
|
|
Sep 11
2023
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+21.73%
|
-
|
|
Sep 11
2023
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+43.69%
|
-
|
|
Sep 11
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
32,351
-12.9%
|
$679,371
$21.97 P/Share
|
|
Sep 11
2023
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+48.62%
|
-
|